TAMPA, Florida – TruPharma, LLC (TruPharma) announced today that it has launched Quetiapine Fumarate ER Tablets on the TruPharma label. FDA has determined that this product is therapeutically equivalent to the reference listed drug (RLD), SEROQUEL® XR Tablets of AstraZeneca Pharmaceuticals LP (AstraZeneca). The product is available in 50 mg (base), 150 mg (base), 200 mg (base), 300 mg (base), and 400 mg (base) strengths. The FDA-approved product is being supplied to TruPharma pursuant to an agreement with Pharmadax USA, Inc. (a subsidiary of Pharmadax, Inc.). SEROQUEL® is a registered trademark of AstraZeneca UK Limited.